Nuveen Asset Management LLC boosted its stake in shares of Apyx Medical Corp (NASDAQ:APYX) by 38.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,881 shares of the company’s stock after acquiring an additional 33,954 shares during the quarter. Nuveen Asset Management LLC owned about 0.36% of Apyx Medical worth $676,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of APYX. EAM Investors LLC bought a new stake in Apyx Medical during the second quarter worth approximately $800,000. JPMorgan Chase & Co. increased its stake in Apyx Medical by 978.5% during the first quarter. JPMorgan Chase & Co. now owns 118,438 shares of the company’s stock worth $425,000 after acquiring an additional 107,456 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Apyx Medical by 273.1% during the second quarter. Goldman Sachs Group Inc. now owns 146,787 shares of the company’s stock worth $815,000 after acquiring an additional 107,448 shares during the last quarter. Taylor Frigon Capital Management LLC grew its stake in shares of Apyx Medical by 14.6% during the second quarter. Taylor Frigon Capital Management LLC now owns 556,451 shares of the company’s stock valued at $3,088,000 after buying an additional 71,021 shares during the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Apyx Medical by 58.6% during the first quarter. Wells Fargo & Company MN now owns 115,610 shares of the company’s stock valued at $415,000 after buying an additional 42,700 shares during the last quarter. 52.35% of the stock is currently owned by institutional investors.

APYX opened at $5.92 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.70 and a current ratio of 7.25. The stock’s 50 day moving average price is $4.95 and its 200-day moving average price is $4.60. Apyx Medical Corp has a one year low of $2.81 and a one year high of $8.59. The stock has a market cap of $202.56 million, a price-to-earnings ratio of -12.08 and a beta of 0.61.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Monday, August 10th. The company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.03. Apyx Medical had a negative net margin of 64.89% and a negative return on equity of 22.98%. The business had revenue of $4.30 million for the quarter, compared to analyst estimates of $2.50 million. As a group, analysts predict that Apyx Medical Corp will post -0.51 earnings per share for the current fiscal year.

Separately, Zacks Investment Research cut Apyx Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, October 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $6.94.

Apyx Medical Profile

Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.

Recommended Story: What is the definition of market timing?

Institutional Ownership by Quarter for Apyx Medical (NASDAQ:APYX)

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.